Top 7 in oncology

A snapshot of the most highly ranked articles in oncology, from Faculty of 1000

Edyta Zielinska
Apr 11, 2011
linkurl:1. Donor match not needed;http://f1000.com/8451957?key=xspfhy56z9z65h3 Elderly acute myeloid leukemia patients who received blood stem cells from non-matching donors after chemotherapy showed marked improvement over patients receiving chemo alone. M. Guo et al., "Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients," linkurl:__Blood,__;http://www.ncbi.nlm.nih.gov/sites/entrez/20966170?dopt=Abstract&holding=f1000%2Cf1000m 117:936-41, 2011. Evaluated by Arati Rao, Duke Univ; Riccardo Varaldo, U of Genova and S Martino Hosp, Italy; Nelson Chao, Duke Univ Med Cntr. linkurl:Free F1000 Evaluation;http://f1000.com/8451957?key=xspfhy56z9z65h3 linkurl:2. Weighing brain radiation therapy;http://f1000.com/7508964?key=bcj5t4djf63y7qx Clinicians have debated whether whole-brain radiation therapy (WBRT) is the appropriate follow-up therapy for CNS lymphoma, a cancer of the immune cells in the brain, because of its relatively high risk of toxicity. A clinical trial suggested that WBRT should not be given to patients who respond well to methotrexate, a first-line drug against the disease, but might improve overall survival for those who don't, though...
E. Thiel et al., High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial," linkurl:__Lancet Oncol,__;http://www.ncbi.nlm.nih.gov/sites/entrez/20970380?dopt=Abstract&holding=f1000%2Cf1000m 11:1036-47, 2010. Evaluated by Priya Kumthekar and Jeffrey Raizer, Northwestern Univ; Roger Abounader and David Schiff, U of Virginia Neuro-Oncology Cntr. linkurl:Free F1000 Evaluation;http://f1000.com/7508964?key=bcj5t4djf63y7qx
Leukemia cells
Image: Wikimedia/ PLoS Biol
linkurl:3. Estimating breast cancer survival;http://f1000.com/9407956?key=pxl81y59j917nqc B.E. Kiely et al., "How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials," linkurl:__J Clin Oncol,__;http://www.ncbi.nlm.nih.gov/sites/entrez/21189397?dopt=Abstract&holding=f1000%2Cf1000m 29:456-63, 2011. Evaluated by Michael Fisch, U of Texas, MD Anderson Cancer Cntr. linkurl:Free F1000 Evaluation;http://f1000.com/9407956?key=pxl81y59j917nqc linkurl:4. Details improve prognosis estimates;http://f1000.com/9390956?key=8q65jpxdb6kxtqv S. Mook et al., "Independent Prognostic Value of Screen Detection in Invasive Breast Cancer," linkurl:__J Natl Cancer Inst,__;http://www.ncbi.nlm.nih.gov/sites/entrez/21350218?dopt=Abstract&holding=f1000%2Cf1000m 103:585-97, 2011. Evaluated by Alberto Quaglia National Cancer Res Inst, Italy. linkurl:Free F1000 Evaluation;http://f1000.com/9390956?key=8q65jpxdb6kxtqv linkurl:5. The genetics of a germline cancer;http://f1000.com/9312958?key=pyf7yvdcqj6rj56 K. Frank-Raue et al., "Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10," linkurl:__Hum Mutat,__;http://www.ncbi.nlm.nih.gov/sites/entrez/20979234?dopt=Abstract&holding=f1000%2Cf1000m 32:51-58, 2011. Evaluated by Rute Tomaz, Jaime Miguel Gomes Pita and Branca Cavaco, Inst Portugues de Oncologia de Lisboa, Portugal. linkurl:Free F1000 Evaluation;http://f1000.com/9312958?key=pyf7yvdcqj6rj56 linkurl:6. Kill all tumor cells;http://f1000.com/9247956?key=y2rcxvw14z2cprj F. Notta et al., "Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells," linkurl:__Nature__;http://www.ncbi.nlm.nih.gov/sites/entrez/21248843?dopt=Abstract&holding=f1000%2Cf1000m 469:362-67, 2011. Evaluated by Anil Sadarangani and Catriona Jamieson, UCSD. linkurl:Free F1000 Evaluation;http://f1000.com/9247956?key=y2rcxvw14z2cprj linkurl:7. Microtubule inhibitors extend survival;http://f1000.com/9304956?key=33bnr9804x10c2h J. Cortes et al., "Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study," linkurl:__Lancet__;http://www.ncbi.nlm.nih.gov/sites/entrez/21376385?dopt=Abstract&holding=f1000%2Cf1000m 377:914-23, 2011. Evaluated by Blair Irwin and Jeffrey Peppercorn, Duke Univ. linkurl:Free F1000 Evaluation;http://f1000.com/9304956?key=33bnr9804x10c2h



Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?